Targeting GM-CSF in Rheumatoid Arthritis: Advances in Cytokine-Directed Immunotherapy and Clinical Implications

Granulocyte-macrophage colony-stimulating factor (GM-CSF) has emerged as a key cytokine in the pathogenesis of rheumatoid arthritis, an autoimmune disease distinguished by synovial inflammation and progressive joint destruction. GM-CSF orchestrates the activation, proliferation, and differentiation of myeloid cells (mainly macrophages and neutrophils) thereby sustaining the pro-inflammatory synovial milieu. Recent advances in monoclonal antibody immunotherapy have enabled selective inhibition of GM-CSF or its receptor. Clinical data on several monoclonal antibodies are presented, focusing on their pharmacodynamic properties and efficacy results documented in phase II and III clinical studies. Cumulative evidence supports GM-CSF inhibition as a compelling strategy for modulating inflammation and improving clinical outcomes in rheumatoid arthritis.